OMA 102
Alternative Names: OMA-102Latest Information Update: 12 Jan 2024
Price :
$50 *
At a glance
- Originator EMS
- Class Skin disorder therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Alopecia
Most Recent Events
- 21 Apr 2023 Clinical trials in Alopecia in Brazil (PO), prior to April 2023
- 21 Apr 2023 EMS plans a phase III trial for Female pattern hair loss in Brazil (NCT05824065)